Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) marched up 260.47% compared to a 52-week low price of $1.29. The shares were last seen trading 18.02% higher, taking the closing price at $4.65 on 7/26/2019. At a recent session, the prices were hovering between $3.885 and $5.03. This company shares are 7.53% off its target price of $5 and the current market capitalization stands at $546.61M. The recent change has given its price a 64.85% lead over SMA 50 and 16.83% lead over its 52-week high. The stock witnessed 73.51% gains, 46.69% gains and 103.95% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACHN’s volatility during a week at 20.5% and during a month it has been found around 8.04%.Achillion Pharmaceuticals, Inc. (ACHN) Top Holders
Institutional investors currently hold around $512 million or 83% in ACHN stock. Look at its top three institutional owners: Rtw Investments, Lp owns $63.94 million in Achillion Pharmaceuticals, Inc., which represents roughly 11.7% of the company’s market cap and approximately 12.49% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 11,933,406 shares of the stock are valued at $55.49 million. The third largest holder is Blackrock Inc., which currently holds $53.3 million worth of this stock and that ownership represents nearly 9.75% of its market capitalization.Achillion Pharmaceuticals, Inc. 13F Filings
At the end of March reporting period, 47 institutional holders increased their position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by some 19,426,191 shares, 52 decreased positions by 12,194,405 and 32 held positions by 78,413,361. That puts total institutional holdings at 110,033,957 shares, according to SEC filings. The stock grabbed 10 new institutional investments totaling 1,131,917 shares while 20 institutional investors sold out their entire positions totaling 3,286,447 shares.Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Insider Trades
Multiple company employees have indulged in significant insider trading. Achillion Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner JOHNSON & JOHNSON has sold 18,367,346 shares of Achillion Pharmaceuticals, Inc. (ACHN) in the trading session dated Nov. 20, 2017. These shares are worth $50,510,202 and were traded at $2.75 each. The SEC filing shows that FISHERMAN JASON S performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Dec. 22, 2016. The company’s shares were assimilated at $3.96 per share worth to an investment of some $39,600 to the account of FISHERMAN JASON S.
CFO, Fenton Mary Kay, purchased 2,500 common shares of Achillion Pharmaceuticals, Inc. (ACHN) in the open market. In a transaction dated Dec. 05, 2016, the shares were bought at an average price of $4.11, giving away a sum of $10,275. After this purchase, 2,500 common shares of ACHN are directly owned by the insider, with total stake valued at $11,625.
In the transaction dated Dec. 02, 2016, a great number of shares acquired came courtesy the Chief Scientific Officer; Barrish Joel C added a total of 2,500 shares at an average price of $4.06, amounting to approximately $10,150. The insider now directly owns 2,500 shares worth $11,625.Achillion Pharmaceuticals, Inc. (ACHN) Analyst Guide
Not many analysts have released their opinion on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation [T1].